Cargando…

Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence

Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawashiri, Takehiro, Mine, Keisuke, Kobayashi, Daisuke, Inoue, Mizuki, Ushio, Soichiro, Uchida, Mayako, Egashira, Nobuaki, Shimazoe, Takao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866815/
https://www.ncbi.nlm.nih.gov/pubmed/33573316
http://dx.doi.org/10.3390/ijms22031393
_version_ 1783648161158397952
author Kawashiri, Takehiro
Mine, Keisuke
Kobayashi, Daisuke
Inoue, Mizuki
Ushio, Soichiro
Uchida, Mayako
Egashira, Nobuaki
Shimazoe, Takao
author_facet Kawashiri, Takehiro
Mine, Keisuke
Kobayashi, Daisuke
Inoue, Mizuki
Ushio, Soichiro
Uchida, Mayako
Egashira, Nobuaki
Shimazoe, Takao
author_sort Kawashiri, Takehiro
collection PubMed
description Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research.
format Online
Article
Text
id pubmed-7866815
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-78668152021-02-07 Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence Kawashiri, Takehiro Mine, Keisuke Kobayashi, Daisuke Inoue, Mizuki Ushio, Soichiro Uchida, Mayako Egashira, Nobuaki Shimazoe, Takao Int J Mol Sci Review Oxaliplatin is an essential drug in the chemotherapy of colorectal, gastric, and pancreatic cancers, but it frequently causes peripheral neuropathy as a dose-limiting factor. So far, animal models of oxaliplatin-induced peripheral neuropathy have been established. The mechanisms of development of neuropathy induced by oxaliplatin have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory effects on neuropathy. In this review, we summarize the basic and clinical evidence for the therapeutic effects of oxaliplatin. In basic research, there are many reports of neuropathy inhibitors that target oxidative stress, inflammatory response, sodium channel, transient receptor potential (TRP) channel, glutamate nervous system, and monoamine nervous system. Alternatively, very few drugs have clearly demonstrated the efficacy for oxaliplatin-induced peripheral neuropathy in clinical trials. It is important to activate translational research in order to translate basic research into clinical research. MDPI 2021-01-30 /pmc/articles/PMC7866815/ /pubmed/33573316 http://dx.doi.org/10.3390/ijms22031393 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Kawashiri, Takehiro
Mine, Keisuke
Kobayashi, Daisuke
Inoue, Mizuki
Ushio, Soichiro
Uchida, Mayako
Egashira, Nobuaki
Shimazoe, Takao
Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title_full Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title_fullStr Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title_full_unstemmed Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title_short Therapeutic Agents for Oxaliplatin-Induced Peripheral Neuropathy; Experimental and Clinical Evidence
title_sort therapeutic agents for oxaliplatin-induced peripheral neuropathy; experimental and clinical evidence
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7866815/
https://www.ncbi.nlm.nih.gov/pubmed/33573316
http://dx.doi.org/10.3390/ijms22031393
work_keys_str_mv AT kawashiritakehiro therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT minekeisuke therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT kobayashidaisuke therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT inouemizuki therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT ushiosoichiro therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT uchidamayako therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT egashiranobuaki therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence
AT shimazoetakao therapeuticagentsforoxaliplatininducedperipheralneuropathyexperimentalandclinicalevidence